Treatment of Idiopathic Multicentric Castleman Disease Without Severe Organ Dysfunction
Clinical Scenario
This protocol addresses idiopathic multicentric Castleman disease (iMCD) in patients without severe organ dysfunction — typically diagnosed in an outpatient setting with a good performance status and no significant organ impairment. These patients are classified as nonsevere iMCD.
Key eligibility criteria defining this population:
- ECOG performance status below 2
- Estimated glomerular filtration rate (eGFR) at or above 30
- Hemoglobin above 8.0 g/dL
- No anasarca, ascites, or pleural/pericardial effusion
- No interstitial pneumonitis with dyspnea
Treatment Approach (partial overview)
First-line therapy centers on an anti–IL-6 monoclonal antibody strategy, with adjunctive corticosteroid use tailored to symptom severity. For patients without marked cytokine-driven symptomatology, a separate alternative approach is also available. The complete regimen — including specific agents, sequencing, corticosteroid guidance, and the full decision algorithm — is accessible in the structured protocol.
Response Goals
Clinical response should become apparent after the first several doses. Monitoring is performed monthly and tracks normalization of key laboratory parameters alongside improvement in constitutional symptoms such as fatigue, anorexia, fever, and weight changes.
References
DOI: 10.1182/blood-2018-07-862334
- iMCD patients who are not severely sick are typically diagnosed in the outpatient setting and have a good performance status without evidence of abnormal organ function, whereas other patients are more symptomatic and often exhibit an IL-6–driven inflammatory response that interferes significantly with their ability to function and work.
- Patients should be classified as nonsevere iMCD if the above criteria are not met.
- We recommend (category 1) using anti–IL-6 mAb therapy with siltuximab (11 mg/kg every 3 weeks) for all patients with nonsevere iMCD based on the high proportion of responders, the rigorous nature of the studies underlying the evidence base, and the low side-effect profile relative to other interventions.
- If siltuximab is not available, tocilizumab (8 mg/kg every 2 weeks) may be used (category 2A).
- If needed, first-line therapy with anti–IL-6 mAb should be accompanied by corticosteroid therapy for initial disease control.
- We recommend rituximab (375 mg/m2 × 4-8 doses) as a first-line alternative to anti–IL-6 mAb therapy for patients with nonsevere iMCD who do not have marked cytokine-driven symptomatology based on a more limited data set (category 2B evidence).
View source ↗